Philip Morris Prepares for Q2 Earnings Amidst Positive Momentum

Jul.17.2023
Tobacco giant Philip Morris is expected to report strong earnings fueled by IQOS and ZYN, despite margin challenges.

Shares of tobacco giant Philip Morris International Inc. (NYSE: PM) continued to show positive momentum on Wednesday, with the stock gaining 6% over the past month. Investors eagerly await the company's second quarter 2023 earnings report, which is scheduled to be released on Thursday, July 20, before the market opens. 

 

Revenue Expectations

Analysts are projecting that Philip Morris will report revenue of $8.6 billion for the second quarter of 2023. This estimate suggests a growth of 10% compared to the same period last year. In the first quarter of this year, the company's revenue saw a 3.5% year-over-year increase, reaching $8 billion. 

 

Earnings Forecast

Philip Morris has provided guidance for adjusted earnings per share (EPS) ranging from $1.42 to $1.47 for the second quarter of 2023. Analysts, on the other hand, estimate EPS of $1.47, which is higher than the $1.32 reported in the same quarter last year. The first quarter of 2023 saw a 4.4% decrease in adjusted EPS, amounting to $1.38. 

 

Strength in IQOS

Philip Morris is expected to benefit from the continued strength of its IQOS product, which has been gaining market share across various regions and showing a rise in adoption. The company noted in its first quarter report that as of March 31, there were approximately 25.8 million IQOS users. Furthermore, with the introduction of the IQOS ILUMA, the product category has experienced further growth, attracting an estimated 10 million users. ILUMA has dominated market volumes in countries like Japan, Switzerland, and Spain, accounting for over 85% of HTU (heated tobacco unit) volumes. Alongside promising growth in developed countries, PMI is witnessing encouraging expansion for IQOS in low and middle-income markets. 

 

Growth of ZYN

Philip Morris will also benefit from the growth of nicotine pouch brand ZYN, which it acquired through the Swedish Match acquisition. In the first quarter, ZYN witnessed a 47% increase in volume in the US. The company sees significant potential to expand distribution and velocity, referring to the number of ZYN cans sold per store per week. 

 

Margin Challenges

In the first quarter, Philip Morris faced challenges with its margins due to inflationary pressures and supply chain obstacles. These pressures are expected to persist through the year, impacting the company's margins. Despite this, Philip Morris continues to make growth investments to support its business expansion. 

 

Investors are eager to see the financial results of Philip Morris International Inc. as the company prepares to release its second quarter 2023 earnings report. With expectations of revenue growth and increased earnings per share, fueled by the robust performance of IQOS and the potential of ZYN, Philip Morris appears to be well-positioned to meet market expectations. However, challenges with margins and inflationary pressures remain an ongoing concern.


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Opinion | As EU Reviews Tobacco Rules, Experts Warn Against Overlooking Smokers’ Alternatives
Opinion | As EU Reviews Tobacco Rules, Experts Warn Against Overlooking Smokers’ Alternatives
As the European Commission reviews its tobacco and advertising rules, two experts who provided written comments to 2Firsts argue that future EU policy should not overlook adult smokers’ alternatives. Dr Garrett McGovern and Dr Carmen Escrig say regulators should weigh relative risk, adult switching, flavours, consumer behaviour and scientific uncertainty alongside youth protection.
Industry Insight
Jun.01
2Firsts Hosts U.S. Compliance Briefing on Building PMTA Support Capabilities Across the Nicotine Supply Chain
2Firsts Hosts U.S. Compliance Briefing on Building PMTA Support Capabilities Across the Nicotine Supply Chain
2Firsts held a U.S. compliance briefing in Shenzhen to help vaping, heated tobacco and nicotine pouch supply chain companies strengthen PMTA support capabilities. The event focused on supplier documentation, quality systems, traceability, TPMF/TPMP pathways, age verification and customer audit readiness as U.S. compliance expectations increasingly extend deeper into the nicotine supply chain.
Events
Jun.12
China Tobacco Yunnan Patent Describes Cigar Flavor Granules With Encapsulation Rate Above 77%
China Tobacco Yunnan Patent Describes Cigar Flavor Granules With Encapsulation Rate Above 77%
According to public records from China’s National Intellectual Property Administration, a patent application filed by China Tobacco Yunnan Industrial Co., Ltd. for “cigar flavor granules” was published on May 12, 2026. The filing proposes purifying an ethanol extract of cigar tobacco leaves using LX-8 macroporous resin, followed by encapsulation with maltodextrin and sucrose fatty acid ester to improve smoking comfort, reduce dryness and enhance aroma release stability in reconstituted tobacco.
Jun.10
U.S. Senator Durbin Criticizes FDA’s First Flavored Vape Authorization, Says Trump Administration Conceded to Big Tobacco
U.S. Senator Durbin Criticizes FDA’s First Flavored Vape Authorization, Says Trump Administration Conceded to Big Tobacco
U.S. Senator Dick Durbin on May 13 criticized the Trump Administration’s Food and Drug Administration for approving the sale and marketing of fruit-flavored e-cigarettes for the first time, while also allowing some illegal vaping products to remain on the market. He also linked the regulatory shift to the departure of FDA Commissioner Marty Makary, saying White House pressure on regulators to approve tobacco product applications could create serious public-health consequences.
Regulations
May.15
AP Questions FDA Rationale as Glas Fruit-Flavored Vapes Won Authorization Without Added Cessation Benefit
AP Questions FDA Rationale as Glas Fruit-Flavored Vapes Won Authorization Without Added Cessation Benefit
The U.S. Food and Drug Administration (FDA) recently authorized two fruit-flavored vaping products from Glas, but a newly released agency memo shows the products did not demonstrate greater smoking-cessation benefits than tobacco-flavored e-cigarettes. The Associated Press said the findings are likely to raise further questions about the FDA’s regulatory rationale and standards for flavored vaping products.
Jun.12
VEEV Arrives in South Korea, Completing PMI’s IQOS-ZYN-VEEV Portfolio
VEEV Arrives in South Korea, Completing PMI’s IQOS-ZYN-VEEV Portfolio
Philip Morris Korea has officially launched its VEEV e-vapor brand in South Korea, introducing both the VEEV inPRIME device and VEEBI inPRIME pods. The launch further expands PMI’s smoke-free portfolio in Korea, alongside its IQOS heated tobacco products and ZYN nicotine pouches.
Jun.16